Deutsche Bank Ag\ Myovant Sciences Ltd. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $54,692 - $61,497	2,276 New	2,276 $61,000
Q4 2021 Feb 11, 2022	SELL	$14.31 - $23.87 $103,962 - $173,415	-7,265 Reduced 76.15%	2,276 $35,000
Q3 2021 Nov 04, 2021	BUY	$18.94 - $26.99 $128,640 - $183,316	6,792 Added 247.07%	9,541 $214,000
Q2 2021 Aug 11, 2021	SELL	$17.07 - $24.56 $256 - $368	-15 Reduced 0.54%	2,749 $63,000
Q1 2021 May 13, 2021	SELL	$20.46 - $25.18 $1.72 Million - $2.12 Million	-84,043 Reduced 96.82%	2,764 $56,000
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $1.16 Million - $2.33 Million	84,278 Added 3332.46%	86,807 $2.4 Million
Q3 2020 Nov 12, 2020	SELL	$14.05 - $22.6 $4.82 Million - $7.76 Million	-343,376 Reduced 99.27%	2,529 $36,000
Q2 2020 Aug 13, 2020	BUY	$7.34 - $20.84 $1.82 Million - $5.16 Million	247,773 Added 252.49%	345,905 $7.13 Million
Q1 2020 May 14, 2020	BUY	$6.55 - $14.76 $615,765 - $1.39 Million	94,010 Added 2280.69%	98,132 $741,000
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $17,312 - $79,183	4,122 New	4,122 $63,000
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $8,044 - $14,663	-1,550 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $13,469 - $38,750	1,550 New	1,550 $14,000
Q3 2018 Nov 14, 2018	SELL	$19.33 - $26.78 $25,244 - $34,974	-1,306 Closed	0 $0
Q2 2018 Apr 21, 2020	BUY	$19.2 - $25.14 $13,555 - $17,748	706 Added 117.67%	1,306 $30,000
Q2 2018 Aug 14, 2018	SELL	$19.2 - $25.14 $12,710 - $16,642	-662 Reduced 52.46%	600 $13,000
Q1 2018 Oct 18, 2019	BUY	$12.46 - $21.32 $15,388 - $26,330	1,235 Added 4574.07%	1,262 $26,000
Q4 2017 Feb 14, 2018	SELL	$11.37 - $16.4 $220,339 - $317,815	-19,379 Reduced 99.86%	27 $0
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $192,701 - $300,210	19,406	19,406 $300,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account